Indeed, in 39 of 61 patients (63.9%), additional private alterations were detected in the recurrence samples only, affecting breast cancer-related genes as ERBB2, ESR1, FGFR1, or NF1, and including 12 patients (19.7%) with clinically relevant alterations according to the OncoKB levels of evidence V2 ranking (levels 1–3) (Additional files 9 and 10). The gene discussed is FGFR1; the disease is breast cancer.